Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets.

Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets. Abstract Text:

R Schaper,J Heine,R G Arther,S D Charles,J McCall,

Ferrets are susceptible to Dirofilaria immitis infection and develop a disease comparable to that in cats and dogs. Treatment options are limited, thus prevention would be a viable alternative. A study was conducted to evaluate the efficacy of a combination of 10% w/v imidacloprid plus 1.0% w/v moxidecin spot-on to prevent patent D. immitis infection in experimentally infected ferrets when administered once 30 days post-infection. Twelve ferrets were acclimated to the study facility for seven days. The ferrets were free of heartworm infection prior to the artificial infection, as demonstrated by negative test results onmicrofilarial and antigen tests. On study day -30, the twelve ferrets were artificially infected with 25 infective, thirdstage larvae of D. immitis. On study day -1, the twelve ferrets were randomised and allocated to two study groups so that each group contained six ferrets. On study day 0, the animals assigned to group 1 were treated with a combination of 10% imidacloprid / 1% moxidectin at a dose of 0.4 ml per ferret. The animals assigned to group 2 served as untreated controls. On study day 124, the ferrets in both study groups were euthanised and necropsied to determine the worm burden. Ferrets in the control group (group 2) were adequately infected with D. immitis at necropsy to allow assessment of the treatment group in this study (GM = 17.2worms). The efficacy of a combination of 10% imidacloprid / 1.0% moxidecin against artificial infections with D. immitis in ferrets was 100% when administered once, at a target dosage of 0.4 ml, 30 days post-infection. No adverse events were observed which were considered to be treatment related.

Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets. Publishing Authors By Initials

R Schaper,J Heine,RG Arther,SD Charles,J McCall,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Parasitology research

VOLUME: 101 Suppl 1

Page Numbers: 57-62

Journal Abbreviation: Parasitol. Res.

ISSN: 0932-0113

DAY: 30

MONTH: Aug

YEAR: 2007

Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8703571

Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets.

AFFILIATION: Bayer HealthCare AG, Animal Health, Leverkusen, Germany, roland.schaper@bayerhealthcare.com.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Parasitol Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Imidacloprid plus Moxidectin to Prevent Heartworm Infection Dirofilaria immitis in Ferrets Related Publications

• A bizarre incident in sterility regime.
• Aldosterone in experimental and clinical medicine.
• An adaptive ERG technique to measure normal and altered dark adaptation in the mouse.
• CHILD HYGIENE: A NEW RAMIFICATION OF THE DENTAL PROBLEM.
• Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs.
• Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers.
• Effects of pain acceptance and pain control strategies on physical impairment in individuals with chronic low back pain.
• Electroconvulsive therapy: all in the family.
• Epigenetic silencing of tumor necrosis factor alpha during endotoxin tolerance.
• Expecting the worst. How disaster management is taking the kidney community by storm.
• Extraperitoneal cesarean section in the profoundly infected patient.
• Imidacloprid plus Moxidectin to Prevent Heartworm Infection (Dirofilaria immitis) in Ferrets.
• Individual invention versus socio-ecological innovation: Unifying the behavioral and evolutionary sciences.
• Malocclusion as a risk factor in the etiology of headaches in children and adolescents.
• Noncanonical cell death pathways act during Drosophila oogenesis.
• Nyctalopin expression in retinal bipolar cells restores visual function in a mouse model of complete x-linked congenital stationary night blindness.
• Oral behaviors checklist: reliability of performance in targeted waking-state behaviors.
• Plasma progestogen levels in pregnant mares following administration of exogenous progesterone.
• Pseudocholinesterase deficiency and electroconvulsive therapy.
• Reversed-phase liquid chromatographic determination of meclozine in biological samples.
• Slipped upper femoral epiphysis: imaging of complications after treatment.
• Source of a problem with Fourier transform spectroscopy.
• Surgical complications of pregnancy.
• The Drosophila caspases Strica and Dronc function redundantly in programmed cell death during oogenesis.
• The axon guidance gene lola is required for programmed cell death in the Drosophila ovary.
• The nasal mucosa in the laryngectomized patients.
• The role of itinerant teachers.
• The role of the cements in pedodontics.
• Toll-like receptor 2 participates in the response to lung injury in a murine model of pulmonary contusion.
• What constitutes successful dental practice?